Menu
Log in


Patent Information Users Group, Inc.

The International Society for Patent Information Professionals

Log in

PIUG 2020 Biotechnology Conference

Taking Biotechnology to the Next Level

Tuesday, February 25, through Wednesday, February 26, 2020

Kimpton Marlowe Hotel
25 Edwin H. Land Blvd.
Cambridge, MA 02141
+1-617-868-8000

Twitter: #PIUG20BIO

Program

Tuesday, February 25, 2020

8:00 am Vendor Set-Up and Breakfast
  Registration, Exhibits open
 

Morning Session

8:30 am Welcoming Remarks and Meeting Logistics
Greg Roland Novartis
Alison Taylor Abbott
8:45 am United States Patent Eligibility: Understanding the Issues and Navigating the New Waters
Leslie Fischer (Keynote) Novartis
9:30 am Past, Present, and Future of CAR T-Cell Technology
Nigel Clarke EPO
10:00 am Examination of Claims Directed to Antibodies at the United States Patent and Trademark Office
Daniel E. Kolker USPTO
10:30 am

Product Reviews
Aptean (GenomeQuest), BizInt, and Derwent

10:45 am

Break & Vendor Exhibits

11:15 am

CAS BioSequences Using STN and GenomeQuest
Anne Marie Clark ScienceIP/CAS

11:45 am Product Reviews
Minesoft, Questel
11:55 am

Lunch & Vendor Exhibits 

 

Afternoon Session

1:30 pm Panel Discussion: Searcher/Practitioner Collaboration
Leslie Fischer Novartis
Anne Marie Clark ScienceIP/CAS
2:30 pm Confident Sequence Searching: Comprehensive Search Best Practices to Avoiding Litigation
Laura Bantle Clarivate
3:00 pm

Product Reviews
Evaluserve, STN

3:10 pm Break & Vendor Exhibits
3:40 pm
4:10 pm Identifying Established and Emerging Biotech Companies in the Global Patent Landscape
Qin Meng and Larry Cady IFI CLAIMS Patent Services
4:40 pm Closing Remarks
5:30 pm Networking Dinner (registration required)

Please note: This information is subject to change, due to circumstances beyond our control.

Meeting Abstracts

Top of Page
United States Patent Eligibility: Understanding the Issues and Navigating the New Waters

Leslie Fischer (Keynote) Novartis

Abstract

United States (U.S.) patent law has historically held that diagnostic-based inventions, along with purified and/or isolated natural products are eligible for patenting. Subject matter as diverse as medical diagnostics, diagnostic kits, vitamins, proteins, DNA and antibiotics have all been the focus of valid U.S. patents. But, in 2012 and 2013, the U.S. Supreme Court introduced uncertainty into the patent eligibility arena, by holding that genomic DNA was not eligible for patenting “merely because” it is isolated, and that a diagnostic-based invention was merely a natural law with nothing more. The U.S. Patent and Trademark Office and various U.S. federal courts have exacerbated this uncertainty with a series of official patent examination guidelines and decisions extending the Supreme Court’s limited holdings to diverse subject matter and inventions. In this lecture, we will explore the concept of what it means to be “patent eligible”, the history of patent eligibility in the natural products field, and the new legal doctrines and how they are negatively impacting U.S. patent eligibility.

Biography

Dr. Leslie Fischer, Ph.D., J.D. is a Principal Patent Attorney at Novartis Pharmaceuticals Corp. in East Hanover, NJ. She focuses on global patent prosecution, freedom to operate, regulatory exclusivity, licensing, contractual negotiations, and due diligences. Her technology area of expertise is biopharmaceutical products, particularly for the treatment of autoimmune diseases. Dr. Fischer is also Novartis Pharmaceutical’s designated liaison to the United States Patent Office (USPTO), a role created to enhance the relationship, facilitate dialogue, and share information between these entities. She also teaches mechanical patent claim drafting as an adjunct professor of law at Seton Hall Law School, in Newark, NJ. Prior to joining Novartis in 2007, Dr. Fischer was an associate attorney at Fitzpatrick, Cella, Harper and Scinto in New York, during which time she provided detailed opinion work for a broad range of clients, consulted on biotechnology litigation, and performed pharmaceutical and biotechnology patent prosecution. Dr. Fischer holds a J.D. from Rutgers University, and a Ph.D. in Biochemistry from Thomas Jefferson University in Philadelphia.

Top of Page
Past, Present, and Future of CAR T-Cell Technology

Nigel Clarke EPO (attending remotely)

Abstract

This presentation is concerned with the emergence of Chimeric Antigen Receptor (CAR) T-cell immunotherapy technology as shown by our studies (Nature Biotechnology, volume 37, pages 370–375, 2019) on  the evolution of published patent applications. CAR T-cell therapy has captured the attention of the public because of the remarkable responses it has produced in some patients for whom all other treatments had stopped working. Our study shows the activity of inventors and applicants, the locations of inventive activity, the preferred territories of patent protection and some cooperation networks. Citation analysis reveals high-impact patents. Investment in manpower (inventor count) shows the commitment of patent applicants to their R&D investment in CAR T-cell therapy.

Biography

Nigel S. Clarke is Manager of the European Patent Office’s IP Knowledge research unit. His work includes patent landscaping and he has recently completed studies on CAR T-cell immunotherapy, blockchain, graphene composites, and quantum sensing and metrology, Current projects include space technology and hydrogen fuelled vehicles.
 
He has authored book chapters and papers on patents, patent information, and innovation, and has lectured widely.
 
Leaving academia, Nigel started work in the UK Scientific Civil Service, mainly on focused energy beams for microanalysis. He published numerous scientific papers.
 
Nigel studied physical chemistry at Exeter University and holds a PhD in neutron science. He carried out post-doctoral research on carbon fibres at Surrey University
 
He holds Memberships of the Royal Society of Chemistry and the Institute of Physics. He is also a Chartered Scientist, UK Science Council. He has external academic positions at a number of UK universities. Nigel is a contributor to the ISO TC279 Innovation Management working group. He is an editorial board member for World Patent Information.

Top of Page
Examination of Claims Directed to Antibodies at the United States Patent and Trademark Office

Daniel E. Kolker USPTO

Abstract

This talk will discuss search strategies that USPTO examiners use in evaluating the patentability of claims drawn to antibodies. The discussion will concentrate on claims to monoclonal antibodies claimed by sequence, but will also discuss how we evaluate claims drawn to antibodies which bind to an epitope. The talk will emphasize search strategies, but will also address inherency under 35 U.S.C. 102 and evaluation of compliance with the written description requirement of 35 U.S.C. 112.

Biography

Daniel Kolker received a bachelor’s degree in psychology from Vassar College in 1992.  He worked as a technician in a small drug company in Cambridge MA for over two years, and then enrolled at Northwestern University’s Institute for Neuroscience.  He received a Ph.D. in neuroscience in 2001, and served as a post-doctoral fellow at the National Institute of Child Health and Human Development.  Upon joining the USPTO as an examiner in TC1600, he examined patent applications in the fields of neurobiology, receptors, and cytokines.  In 2012, he became a supervisory patent examiner (SPE) and currently oversees art unit 1644, which examines applications in immunology. As a supervisor he works closely with junior examiners in the art unit, and is an expert on patent subject matter eligibility, particularly in the biotechnology area. 

Top of Page
Confident Sequence Searching: Comprehensive Search Best Practices to Avoiding Litigation

Laura Bantle Clarivate

Abstract

The use of multiple databases and search algorithms is essential to patent searchers exploring patentability and clearance searches for life science inventions. Concise keyword and fielded search techniques are essential for conducting a comprehensive sequence alignment exploration in the prior art.

This talk will review search techniques and best practices within both sequence and patent databases to help retrieve highly relevant results. Examples will include previously litigated patents subject to invalidity or inequitable conduct challenges.

Biography

Laura Bantle is a registered US patent attorney and is a member of the Minnesota Bar. Laura earned her B.S. from the College of Biological Sciences at the University of Minnesota, and graduated magna cum laude from William Mitchell College of Law. Prior to joining Clarivate Analytics, Laura gained corporate industry experience in pharmaceutical regulatory compliance and patent licensing.

Top of Page
CAS BioSequences using STN and GenomeQuest

Anne Marie Clark ScienceIP/CAS

Abstract

CAS Biosequences are now available on two platforms - STN and GenomeQuest. Each platform has its relative strengths depending on the search and customer requirements. The presentation will describe typical searches, platform / content used, including example search strategies with BLAST,  Motif and modified nucleotides.

Biography

Anne Marie Clark, Ph.D. is a Senior Searcher with the Science IP team. Her particular subject expertise is small molecules, sequences and formulations.  She is skilled in patent searching, analysis and landscaping, as well as competitive benchmarking.

Top of Page
Trends in Biotechnology Innovation: An Analysis of Global Patent Filings Featuring Biosequences

Caroline Peel Clarivate

Abstract

Trends in Biotechnology Innovation: An Analysis of Global Patent Filings Featuring Biosequences
Advancements in biotechnology have made the large-scale development of biological drugs easier and more cost-effective. While chemical based drugs remain prevalent, the total share of biologic drugs has increased significantly in recent years, representing more than 25% of the pharmaceutical market and is anticipated to reach US$ 727 billion in annual revenue by 2025.  Additionally, the rising global burden of major diseases including cardiovascular disease and cancer, and the need to invest in sustainable food production, are contributing factors driving governments and private organisations to invest more in biotechnology innovation.

Based on a 2019 analysis of patent data, this presentation will focus on innovation trends advancing biotechnology. The discussion will explore global and regional patent activity for biosequences, the leading technology areas and the top innovators pursuing biotechnology and biopharma solutions. Further, the analysis of biosequence innovation trends can provide biotechnology and biopharma patent information professionals clear insights into who, what and where are driving the developing technology landscape.  

Biography

Dr Caroline Peel is the Head of Content Operations for IP and Standards at Clarivate Analytics, leading the editorial curation of patent content for products including Derwent Global Patent Data Collection, Derwent World Patents Index and Derwent GENESEQ. Caroline has been part of the Clarivate team for 18 years. Caroline graduated from the University of Leicester with a BSc Hons Degree in Biological Sciences (Genetics) and a PhD in Cell Cycle Genetics from the University of Sheffield.

Top of Page
Identifying Established and Emerging Biotech Companies in the Global Patent Landscape

Qin Meng and Larry Cady IFI CLAIMS Patent Services

Abstract

We have recently analyzed global patent filings related to CRISPR technology. We will present the results of this analysis including country-level activity and top patent fling organizations in the leading countries. Legal status and CPC data will shown. China is very active in the area of CRISPR, as we will show.

Biography

Qin consults with customers in the Asia Pacific region to provide global patent data solutions appropriate to their needs. Prior to joining IFI, she worked as a patent information searcher and information specialist, concentrating on the pharmaceutical and chemical industries.
 
Larry Cady is an experienced patent data analyst and conducts research in support of IFI's clients and partners. Before joining IFI CLAIMS, Larry was VP of Product Management at Thomson Scientific, responsible for IP products. He led the launch of Thomson Innovation and the expansion of Thomson's Asian language data coverage. He also led product management and customer service at MicroPatent prior to its acquisition by Thomson.

© 2020 The Patent Information Users Group, Inc.   

Mailing Address:  40 E. Main St., #1438

Newark, DE  19711

Phone: +1 (302) 660-3275   Fax: +1 (302) 660-3276

Email: PIUGinfo@piug.com

Follow PIUG:  

Go to PIUG wiki

Notice on use of PIUG name and logo:  

No one may use the PIUG name or logo for any promotional or commercial purpose or any other purpose without the prior written consent of the PIUG Board of Directors.  


Powered by Wild Apricot Membership Software